Patents by Inventor Hugh McTavish

Hugh McTavish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Topical immunosensitizers to treat viral and fungal infections
    Patent number: 11957783
    Abstract: A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 16, 2024
    Assignee: Squarex Pharmaceutical Corporation
    Inventors: Hugh McTavish, Thomas Dag Horn
  • INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20220211862
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
    Patent number: 11324834
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: May 10, 2022
    Assignee: IGF Oncology, LLC
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERS
    Publication number: 20210393932
    Abstract: Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 23, 2021
    Inventor: Hugh McTavish
  • DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERS
    Publication number: 20210393542
    Abstract: Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied.
    Type: Application
    Filed: July 17, 2020
    Publication date: December 23, 2021
    Inventor: Hugh McTavish
  • TOPICAL IMMUNOSENSITIZERS TO TREAT VIRAL AND FUNGAL INFECTIONS
    Publication number: 20210186863
    Abstract: A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Hugh McTavish, Thomas Dag Horn
  • NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION
    Publication number: 20210145962
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 20, 2021
    Inventor: Hugh McTavish
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 10967049
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: April 6, 2021
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
    Patent number: 10940197
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: March 9, 2021
    Assignee: Squarox, LLC
    Inventor: Hugh McTavish
  • Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
    Patent number: 10744084
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: August 18, 2020
    Assignees: Squarex, LLC, Bioventures, LLC
    Inventors: Hugh McTavish, Thomas Dag Horn, Sandra Marchese Johnson
  • Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof
    Publication number: 20190336580
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 7, 2019
    Inventor: Hugh McTavish
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 10391147
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: October 8, 2017
    Date of Patent: August 27, 2019
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION
    Publication number: 20190151441
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 23, 2019
    Inventor: Hugh McTavish
  • NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION
    Publication number: 20190105263
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Application
    Filed: November 9, 2018
    Publication date: April 11, 2019
    Inventors: Hugh McTavish, Thomas Dag Horn, Sandra Marchese Johnson
  • Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
    Patent number: 10245314
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Grant
    Filed: August 20, 2017
    Date of Patent: April 2, 2019
    Assignee: Squarex, LLC
    Inventor: Hugh McTavish
  • INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20180333501
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Application
    Filed: June 12, 2018
    Publication date: November 22, 2018
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof
    Publication number: 20180021408
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Application
    Filed: October 8, 2017
    Publication date: January 25, 2018
    Inventor: Hugh McTavish
  • NON-SPECIFIC DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TREAT HERPES SIMPLEX VIRUS INFECTION
    Publication number: 20170340731
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Application
    Filed: August 20, 2017
    Publication date: November 30, 2017
    Inventor: Hugh McTavish
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 9801923
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: October 31, 2017
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof
    Publication number: 20170266260
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Application
    Filed: May 29, 2017
    Publication date: September 21, 2017
    Inventor: Hugh McTavish